Some version of this question arrives constantly: can I take my GLP-1 with insulin, or is one instead of the other, and do they do the same thing? The confusion is not a failure of attention. The two medicines genuinely get talked about in the same breath, in the same clinics, and often in the same sentence in the news.
The short answer is that they are different medicines doing different jobs, they are not interchangeable, and they are sometimes prescribed together on purpose. The longer answer, in plain language, is the rest of this article.
Why the two get mixed up
Start with the surface similarities, because they explain most of the confusion. Both medicines are injected, usually by the person taking them. Both are about blood sugar, at least in their original territory. Both names appear in diabetes conversations and, more recently, in weight conversations, sometimes so close together that a headline can mention one and mean the other.
The confusion has real consequences, which is why it is worth untangling rather than shrugging off. The two medicines behave differently in the body, they measure their doses differently, and the safety picture changes when both are in play. Someone who understands which is which is better placed to follow their own plan, notice what matters, and ask better questions at appointments.
So here is each medicine in turn, plainly, and then what happens when they share a treatment plan.
What insulin does
Insulin is a hormone the body needs in order to move glucose out of the blood and into the cells that use it. Insulin therapy supplies that hormone, and it lowers blood glucose directly. It does its job whether or not you have eaten, which is precisely where its main risk lives: insulin on its own can push blood sugar too low, because it does not wait for a meal to act.
That risk is not a flaw in the medicine. It is the direct consequence of the job insulin does, and it is why the routines around insulin, the timing, the meals, the monitoring, exist in the first place. What low blood sugar feels like, and the situations on a GLP-1 when lows become possible at all, is covered in GLP-1s and Blood Sugar: When Lows Become Possible.
What a GLP-1 does
A GLP-1 receptor agonist does a different job through a different door. It imitates an incretin hormone, one of the signals the gut releases around eating. The hormone itself has its own story, told in What Is GLP-1, the Hormone Behind the Headlines?, but the practical shape is this: the medicine rides along with mealtime signals.
That riding along is the key to its safety profile. A GLP-1's effect on insulin release is glucose dependent: it acts when glucose is present, around food, and fades when there is nothing to act on. That is why a GLP-1 on its own carries a low risk of hypoglycemia. The medicine is not supplying the hormone insulin at all, so it cannot push glucose down in the unconditional way insulin can.
It does two other things insulin does not: it slows how fast the stomach empties, which is behind both the appetite effect and some of the digestive side effects, and it reduces appetite, which is behind much of its use in weight management.
GLP 1 Tracker AppKeep the GLP-1 side of your plan in one place: medication, dose in milligrams, site and a note on every entry.
Get the app
Not substitutes for each other
Because both are injected and both touch blood sugar, a natural assumption grows that one might stand in for the other. The labeling addresses it head on. The Ozempic label states that it is not a substitute for insulin, and that it is not indicated for people with type 1 diabetes or for diabetic ketoacidosis.
That is not a hedge or a legal nicety; it follows directly from the mechanism. A GLP-1 works through incretin signals that assume a working insulin system downstream. It cannot replace insulin the body is not making, and the situations where insulin matters most immediately are exactly the situations the label carves out. A GLP-1 replacing insulin is not a possibility to weigh; it is a category error.
The practical takeaway for anyone on both medicines follows from the same place: never skip, delay or reduce insulin because of anything a GLP-1 does or seems to do. The two plans interact, and the person who manages that interaction is the prescriber.
What changes when they are used together
Now the common and entirely legitimate case: the two prescribed together, which happens often in type 2 diabetes, because they address the picture from different angles.
What changes is the low-blood-sugar math. When a GLP-1 is started alongside insulin or a sulfonylurea, the risk of low blood sugar goes up. In response, prescribers may lower the insulin or sulfonylurea dose, and they may ask for more blood glucose monitoring while the new balance settles. Those are the adjustments the combination calls for, and they come from the prescriber, made with the whole treatment plan in view.
The sentence worth underlining is the last one. Nobody should adjust insulin on their own, in either direction: not downward because the GLP-1 seems to be working, and not upward to compensate for anything. The same goes for a sulfonylurea. The combination is managed, not improvised, and the monitoring a prescriber asks for alongside it is part of the management, not a formality.
Giving both: what the label says
The practical administration facts for the combination are few and clear. When the two medicines are used together, the label says to give them as separate injections, and never to mix them in one syringe. Beyond that, it is acceptable to inject them in the same body region, as long as the two injections are not right next to each other.
In other words, same neighborhood, different address, and never in the same vessel. The general habits around choosing and rotating sites apply to each injection as usual, which is its own subject in GLP-1 Injection Site Rotation: Why It Matters and How to Track It.
The units differ too, and the difference is worth noticing because it is where mix-ups surface. Insulin is measured in units and is often taken more than once a day. GLP-1s are measured in milligrams and are taken weekly or daily depending on the product. Two schedules, two vocabularies, two separate entries in whatever record you keep.
Tracking the GLP-1 side
Which raises the record itself. If your plan includes both medicines, the GLP-1 side has an easy home: the app's dose log records the medication, the dose in milligrams, the injection site and a note, on every entry, so the weekly or daily rhythm and everything you observed around it sits in one place.
A record of blood glucose belongs wherever your care team asks for it. Different teams want it in different places, and the monitoring that accompanies a combined plan is exactly the kind of thing to clarify at the appointment rather than assume.
That is the shape of the whole subject, in the end. Two injected medicines, often discussed together, doing jobs that overlap in conversation and nowhere else in the body. What each one is for, what changes when both are prescribed, and which decisions belong to whom: understanding those three things clears up most of the confusion, and everything past them is a conversation with your care team.
Frequently asked questions
Is a GLP-1 medication a substitute for insulin?
No. The Ozempic label states plainly that it is not a substitute for insulin, and the same logic applies across the class. Insulin supplies a hormone the body needs in order to move glucose out of the blood, and a GLP-1 receptor agonist does a different job entirely, working through gut hormones released around eating. A GLP-1 cannot stand in for insulin, and nobody should stop or change insulin because a GLP-1 has been started. That decision belongs to the prescriber.
Can a GLP-1 and insulin be prescribed together?
Yes, and in type 2 diabetes they often are, because the two address the picture from different angles. When a GLP-1 is started alongside insulin or a sulfonylurea, the risk of low blood sugar goes up, so a prescriber may lower the insulin or sulfonylurea dose and ask for more blood glucose monitoring. Those changes come from the prescriber, who can see the whole treatment plan. Nobody should adjust insulin on their own.
Do GLP-1s cause low blood sugar the way insulin can?
A GLP-1 on its own carries a low risk of hypoglycemia, and the reason is in the mechanism: its effect on insulin release is glucose dependent, so it pushes hardest when glucose is high after eating. Insulin lowers blood glucose directly whether or not you have eaten, which is why insulin on its own can push blood sugar too low. The picture changes when a GLP-1 is combined with insulin or a sulfonylurea, when the risk rises and monitoring matters more.
Do I inject my GLP-1 and my insulin in the same place?
The label's rule for using both is that they are given as separate injections and never mixed in one syringe. It is acceptable to inject them in the same body region, as long as the two injections are not right next to each other. So the same general area is fine, but not the identical spot. Beyond that, the usual rotation habits apply to each medicine on its own schedule.
Can someone with type 1 diabetes use a GLP-1 instead of insulin?
No, and the label is explicit about it: the Ozempic labeling states it is not indicated for people with type 1 diabetes or for diabetic ketoacidosis. The underlying reason is the mechanism. A GLP-1 works through incretin hormones and cannot replace the insulin the body is not producing. Anyone with type 1 diabetes who is curious about these medicines should raise it with their own care team, who know their situation.